Zheng Ao

Zheng Ao

Auto-generated profile, based on publicly available information

Zheng Ao

Obsidian Therapeutics, Cambridge, Massachusetts

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2026 in Cancer Immunology Research
Verified
Journal Article
Open access
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Autologous tumor-infiltrating lymphocyte (TIL) cell therapy is showing promising efficacy against immunologically “hot” tumors such as melanoma, cervical cancer, and renal cancer. However, generation of tumoricidal TILs from “cold” tumors with a low tumor mutational burden, such as many sarcoma types, poses a challenge due to limited infiltration of the tumor microenvironment (TME) with lymphocytes, low frequencies of tumor antigen–specific, high-affinity T cells, and incompletely understood mechanisms of immune-resistance prevailing in the TME. Here, we report the successful generation and expansion of TILs engineered with regulatable, membrane-bound IL15 (cytoTIL15 cells) from immune-excluded, paucicellular chondrosarcoma biopsies largely consisting of collagenous matrix and demonstrate that these cells have potent tumor-killing capacity in cell culture and in tumor spheroid models in the absence of exogenous IL2. Comprehensive spatial profiling of the TME revealed ubiquitous collagen and myeloid infiltration as major resistance mechanisms, whereas lymphocytic infiltration was largely restricted to peripheral regions of the tumors, a relevant consideration when sampling these tumors for TIL harvest. Moreover, we demonstrate that IL15 reduced the signaling threshold of T-cell receptors isolated from TIL clonotypes, increasing their infiltration and cytotoxicity in autologous 3D tumor models. These results suggest the possibility of developing an effective IL2-free TIL therapy for patients with immune-excluded tumors.

2 June 2026
Verified
Other
Open access
PDF file
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Supplementary Table S1: IHC antibody clones and dilution factors

2 June 2026
Verified
Other
Open access
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Supplementary Table S2: Flow cytometry antibodies clones and dulution factors

2 June 2026
Verified
Other
Open access
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Supplementary Figure S7: Representative IHC images of Chondrosarcoma tumors.

2 June 2026
Verified
Other
Open access
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Supplementary Figure S1: Gating strategy for pre-REP phenotyping.

2 June 2026
Verified
Other
Open access
ZAZheng Ao
Zheng Ao
RARusul Al-Marayaty
Rusul Al-Marayaty
BABulent Arman Aksoy
Bulent Arman Aksoy
FOFarres Obeidin
Farres Obeidin
RBRachel Burga
Rachel Burga
SPSeth Pollack
Seth Pollack
Supplementary Figure S5: Nanostring analysis of different sarcoma types.